Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 24051437)

1.

Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.

Yoshimaru T, Komatsu M, Matsuo T, Chen YA, Murakami Y, Mizuguchi K, Mizohata E, Inoue T, Akiyama M, Yamaguchi R, Imoto S, Miyano S, Miyoshi Y, Sasa M, Nakamura Y, Katagiri T.

Nat Commun. 2013;4:2443. doi: 10.1038/ncomms3443.

2.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

3.

Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer.

Yoshimaru T, Komatsu M, Miyoshi Y, Honda J, Sasa M, Katagiri T.

Cancer Sci. 2015 May;106(5):550-8. doi: 10.1111/cas.12654. Epub 2015 Apr 1.

PMID:
25736224
4.

Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer.

Kim JW, Akiyama M, Park JH, Lin ML, Shimo A, Ueki T, Daigo Y, Tsunoda T, Nishidate T, Nakamura Y, Katagiri T.

Cancer Sci. 2009 Aug;100(8):1468-78. doi: 10.1111/j.1349-7006.2009.01209.x. Epub 2009 May 6.

PMID:
19496786
5.

AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.

Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M.

Cell Signal. 2014 May;26(5):1021-9. doi: 10.1016/j.cellsig.2014.01.018. Epub 2014 Jan 24.

PMID:
24463007
6.

MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S, Konduri SD.

Mol Med. 2012 Sep 7;18:913-29. doi: 10.2119/molmed.2012.00010. Erratum in: Mol Med. 2012;18: doi/10.2119/molmed.2012.00006.erratum.

7.

An epigenomic approach to therapy for tamoxifen-resistant breast cancer.

Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW.

Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.

8.

Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions.

Yoshimaru T, Komatsu M, Tashiro E, Imoto M, Osada H, Miyoshi Y, Honda J, Sasa M, Katagiri T.

Sci Rep. 2014 Dec 8;4:7355. doi: 10.1038/srep07355.

9.

O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.

Kanwal S, Fardini Y, Pagesy P, N'tumba-Byn T, Pierre-Eugène C, Masson E, Hampe C, Issad T.

PLoS One. 2013 Jul 11;8(7):e69150. doi: 10.1371/journal.pone.0069150. Print 2013.

10.

Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.

Han Y, Yang L, Suarez-Saiz F, San-Marina S, Cui J, Minden MD.

Mol Cancer Res. 2008 Aug;6(8):1347-55. doi: 10.1158/1541-7786.MCR-07-2179.

11.

Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.

Zhang B, Zhang X, Tang B, Zheng P, Zhang Y.

Breast Cancer Res Treat. 2012 Nov;136(2):399-406. doi: 10.1007/s10549-012-2263-6. Epub 2012 Sep 30.

PMID:
23053650
12.

Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.

Wei C, Cao Y, Yang X, Zheng Z, Guan K, Wang Q, Tai Y, Zhang Y, Ma S, Cao Y, Ge X, Xu C, Li J, Yan H, Ling Y, Song T, Zhu L, Zhang B, Xu Q, Hu C, Bian XW, He X, Zhong H.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):E601-10. doi: 10.1073/pnas.1316255111. Epub 2014 Jan 21.

13.

Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.

Perez White B, Molloy ME, Zhao H, Zhang Y, Tonetti DA.

Mol Cancer. 2013 May 1;12:34. doi: 10.1186/1476-4598-12-34.

14.

Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance.

Louie MC, McClellan A, Siewit C, Kawabata L.

Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.

15.

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.

Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.

Breast Cancer Res Treat. 2010 Jul;122(2):395-407. doi: 10.1007/s10549-009-0581-0. Epub 2009 Oct 22.

PMID:
19847644
16.

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.

Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, Isacke CM.

Oncogene. 2010 Aug 19;29(33):4648-57. doi: 10.1038/onc.2010.209. Epub 2010 Jun 7.

PMID:
20531297
18.

BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells.

Kim NH, Yoshimaru T, Chen YA, Matsuo T, Komatsu M, Miyoshi Y, Tanaka E, Sasa M, Mizuguchi K, Katagiri T.

PLoS One. 2015 Jun 8;10(6):e0127707. doi: 10.1371/journal.pone.0127707. eCollection 2015.

19.

Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.

Endocr Relat Cancer. 2006 Dec;13(4):1121-33.

20.

Clinical significance of estrogen receptor phosphorylation.

Murphy LC, Seekallu SV, Watson PH.

Endocr Relat Cancer. 2011 Jan 19;18(1):R1-14. doi: 10.1677/ERC-10-0070. Print 2011 Feb. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk